v3.26.1
Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development (“R&D”) expenses, net $ (315) $ 5,250
General and administrative expenses 1,611 2,506
Operating loss 1,296 7,756
Other expenses (income) (147) 6
Net gain from deconsolidation of subsidiary (1,860)
Interest expenses 192 5
Day one loss upon entering transaction 5,226
Loss (income) from change in derivatives financial instruments measured at fair value 14,056 (914)
Finance expense, net 377 805
Net loss before tax 19,140 7,658
Tax expenses 1
Net loss $ 19,140 $ 7,659
Basic loss per share of Common Stock (in Dollars per share) $ 7.38 $ 6.27 [1]
Diluted loss per share of Common Stock (in Dollars per share) $ 7.38 $ 6.27 [1]
Weighted average number of shares used in computing basic loss per share of Common Stock (in Shares) 2,603,807 1,215,953 [1]
[1] All share amounts have been retroactively adjusted to reflect a 1-for-19 reverse share split as discussed in Note 7A.